Clinical development of humanized monoclonal antibodies (mAb) against vascular endothelial growth factor (VEGF) highlighted the potential of bevacizumab as a possible target therapy for the treatment of HGG, since VEGF is an important stimulus for angiogenesis and possibly tumor invasion. Here, VEGFA is linked to neoplasm.